Theranostics of Metastatic Prostate Cancer Applying 64Cu/18F/68Ga PSMA PET-CT and 177Lu Radiopharmaceuticals.
Curr Radiopharm
; 14(4): 354-358, 2021.
Article
in En
| MEDLINE
| ID: mdl-32900357
ABSTRACT
The successful use of theranostic twins in neuroendocrine tumors (NET) is the pioneering approach to radionuclide therapy in other tumor types. 64Cu/18F PSMA for molecular imaging with PET-CT and peptide radioligand therapy (PRLT) with 177Lu labeled PSMA inhibitors are the next theranostic twins in nuclear medicine. 68Ga/ 64Cu/18F PSMA PET-CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity and can be used to select patients for PRLT and evaluate therapy response. Radionuclide therapy with 177Lu-PSMA inhibitors has been shown to be effective in the treatment of metastatic CRPC.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Radiopharmaceuticals
/
Precision Medicine
/
Prostatic Neoplasms, Castration-Resistant
/
Positron Emission Tomography Computed Tomography
Type of study:
Diagnostic_studies
Limits:
Humans
/
Male
Language:
En
Journal:
Curr Radiopharm
Year:
2021
Document type:
Article
Affiliation country:
Austria